For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the vectibix (panitumumab) industry by 2029?
The vectibix (panitumumab) market size has grown strongly in recent years. It will grow from $1,269.97 million in 2024 to $1,373.61 million in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to improved overall survival rates in clinical trials, favorable reimbursement policies in developed markets, financial support programs for patients, educational initiatives for oncologists on genetic testing, expanded access to advanced diagnostics in developing regions.
The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $1,853.91 million in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing prevalence of metastatic colorectal cancer (mcrc) globally, growing focus on personalized medicine, increasing healthcare spending in emerging markets, growing adoption of biologics in oncology, increasing focus on patient quality of life. Major trends in the forecast period include advancements in anti-EGFR therapies, partnerships and collaborations between pharmaceutical companies, integration of advanced diagnostic tools, development of companion diagnostics, adoption of next-generation sequencing.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19944&type=smp
Which industry-specific innovations are acting as key drivers for the vectibix (panitumumab) market?
The increasing prevalence of colorectal cancer is expected to propel the growth of the vectibix (panitumumab) market going forward. Colorectal cancer is a cancer that starts in the colon or rectum, typically influenced by genetic, lifestyle, or environmental factors. The rising prevalence of colorectal cancer can be attributed to factors such as an aging population, better survival rates, genetic predispositions, and environmental influences. Vectibix (panitumumab) is a monoclonal antibody that targets and inhibits the epidermal growth factor receptor (EGFR), which helps slow tumor growth and progression in patients with wild-type KRAS tumors, thus offering an effective therapeutic option for those who have not responded to conventional chemotherapy treatments. For instance, in September 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, the global burden of colorectal cancer is expected to rise significantly by 2040, with 3.2 million new cases annually, marking a 63% increase. Deaths from colorectal cancer are also projected to grow, reaching 1.6 million per year, with an increase of 73%. Therefore, the increasing prevalence of colorectal cancer is expected to propel the growth of the vectibix (panitumumab) market.
Increasing Demand For Personalized Medicine Drives Growth In The Vectibix Market
The rising demand for personalized medicine is expected to propel the growth of the vectibix (panitumumab) market going forward. Personalized medicine is an approach to healthcare that customizes treatments and strategies based on the unique characteristics, needs, and preferences of each patient. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Vectibix (panitumumab) is used for personalized medicine by targeting the epidermal growth factor receptor (EGFR) on cancer cells, enabling tailored treatment for patients with metastatic colorectal cancer whose tumors express wild-type EGFR, thereby optimizing therapeutic efficacy and minimizing unnecessary side effects based on individual genetic profiles. For instance, in February 2023, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA’s Center for Devices and Radiological Health, along with the Center for Biologics Evaluation and Research, approved or granted clearances for several important new or expanded indications across 12 in vitro diagnostic testing applications in 2022. Therefore, the rising demand for personalized medicine is driving th e growth of the vectibix (panitumumab) market.
Which segment currently leads the vectibix (panitumumab) market in terms of revenue share?
The vectibix (panitumumab) market covered in this report is segmented –
1) By Distribution Channel: Hospital Pharmacies; Online Pharmacies
2) By Application: Colorectal Cancer Treatment; Other Cancer Treatments
3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/vectibix-panitumumab-global-market-report-
What future trends will impact the direction of the vectibix (panitumumab) industry?
The key trend in the vectibix (panitumumab) market is focusing on developing molecular diagnostic products, such as companion diagnostic kits, to ensure personalized treatment. Companion diagnostic kits are tests designed to identify specific biomarkers or genetic mutations in patients, helping to determine whether they are likely to benefit from a particular therapeutic treatment. For instance, in October 2023, EntroGen Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab). The CRCdx RAS Mutation Detection Kit is a unique molecular diagnostic tool that represents a significant advancement in precision medicine for colorectal cancer (CRC) patients. It is the first real-time PCR-based test in the U.S. to receive premarket approval (PMA) and fully meet the biomarker identification requirement for Vectibix. This innovative kit is designed to accurately detect mutations in KRAS and NRAS exons 2, 3, and 4, offering high sensitivity and specificity. It enables clinicians to efficiently identify patients most likely to benefit from vectibix therapy, minimizing unnecessary side effects and treatment costs.
Who are the top competitors in the global vectibix (panitumumab) market?
Major companies operating in the vectibix (panitumumab) market include Amgen Inc.
What regional dynamics are shaping the future of the global vectibix (panitumumab) market?
North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vectibix (panitumumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Vectibix (panitumumab) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19944
Need Customized Data On Vectibix (panitumumab) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19944&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
